

Resource Summary Report

Generated by [NIF](#) on Sep 23, 2026

NCI-H196

RRID:CVCL_1509

Type: Cell Line

Proper Citation

RRID:CVCL_1509

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1509

Proper Citation: RRID:CVCL_1509

Description: Cell line NCI-H196 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung sarcomatoid carcinoma

Defining Citation: [PMID:2985257](#), [PMID:2986243](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:11030152](#), [PMID:17426248](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:32586373](#), [PMID:35839778](#), [PMID:38180245](#)

Comments: Caution: Originally classified as originating from a lung small cell carcinoma, but is reclassified as a lung sarcomatoid carcinoma based on a number of criteria (PubMed=38180245)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H196

Synonyms: H196, H-196, NCIH196

Cross References: BTO:BTO_0003027, CLO:CLO_0008033, EFO:EFO_0006668, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5823, BioSample:SAMN03471881, BioSample:SAMN10988217,

cancer cell lines: CVCL_1509, Cell_Model_Passport:SIDM00761, CLS:300390, Cosmic:852003, Cosmic:953990, Cosmic:1995546, Cosmic-CLP:1240186, DepMap:ACH-000752, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240186, GEO:GSM169451, GEO:GSM170732, GEO:GSM170733, GEO:GSM784210, GEO:GSM827362, GEO:GSM844633, GEO:GSM845541, GEO:GSM887392, GEO:GSM888470, GEO:GSM986170, GEO:GSM1670201, GEO:GSM1887889, GEO:GSM1887969, KCLB:90196, LiGeA:CCLE_482, LINCS_LDP:LCL-1813, PharmacDB:NCIH196_1051_2019, PRIDE:PXD011896, PRIDE:PXD030304, Progenetix:CVCL_1509, Wikidata:Q54907886

ID: CVCL_1509

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260920T004614+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H196.

Warning: Discontinued: KCLB; 90196

Caution: Originally classified as originating from a lung small cell carcinoma, but is reclassified as a lung sarcomatoid carcinoma based on a number of criteria (PubMed=38180245)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Campisi M, et al. (2026) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer. Cancer cell, 44(4), 858.

Ahmad T, et al. (2026) KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage. bioRxiv : the preprint server for biology.

Coussens NP, et al. (2025) Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclast, and dasminapant in multi-cell type tumor spheroids. SLAS discovery : advancing life sciences R & D, 33, 100230.

De Rosa C, et al. (2025) DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. iScience, 28(3), 111943.

Flor AC, et al. (2025) Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites. *Redox biology*, 80, 103504.

Fnu T, et al. (2025) Sympathetic Neurons Promote Small Cell Lung Cancer through the ? 2-Adrenergic Receptor. *Cancer discovery*, 15(3), 616.

Iñáñez A, et al. (2025) The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. *International journal of molecular sciences*, 26(3).

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. *Cell reports. Medicine*, 5(12), 101852.

Dexheimer TS, et al. (2023) Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. *Cancer research communications*, 3(8), 1648.

Lukinovi? V, et al. (2022) SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. *Cancer discovery*, 12(9), 2158.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. *Cell reports*, 39(7), 110814.

Thomas A, et al. (2021) Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. *Cancer cell*, 39(4), 566.

Schenk MW, et al. (2021) Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. *Nature communications*, 12(1), 6652.